Ergomed Reveals Expansion Plan in Orphan Drugs
Ergomed has unveiled a plan to acquire PSR Group BV, the specialist orphan drug CRO, for a sum of up to €5.7 million (around $6.7 million).
PSR was established in 1998 and is based in the Netherlands, and has extensive experience in rare diseases. These severe, debilitating or even life-threatening conditions affect fewer than 1 in 2000 people (European Union definition) or fewer than 200,000 people in the U.S., according to a statement from Ergomed. Around 30 million people worldwide suffer from rare diseases, and the orphan drug market to target these diseases continues to grow and requires specialist providers due to the regulatory, logistical, and operational complexities of conducting clinical trials, it continued.
As part of the deal, Ergomed said it will continue to grow PSR’s global orphan drug development business under the PSR brand and will remain focused on its two divisions: PSR Orphan Experts, which helps biotech and pharma companies with their regulatory and clinical development of orphan drugs (about 75% of total revenue); and PSR Pharma Resource, which provides specialist trained staff (about 25% of revenue).
The acquisition will extend Ergomed’s global coverage and increase its presence in the Middle East and North Africa, which is an important area for orphan drug development, stated the company.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
